Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. - Wikidata - awgldk - TriplyDB

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

http://www.wikidata.org/entity/Q53241753

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score Treatment of diffuse large B cell lymphoma Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Biomarkers of HIV-associated Cancer.Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP.Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study.Genetic lesions in diffuse large B-cell lymphomas Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.Hematolymphoid Lesions of the Sinonasal Tract.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma.Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features New Challenges in the Management of Diffuse Large B-Cell Lymphoma.Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3 CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study.Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma

P2860

Q24597424-6718A9B9-7A0A-4AA4-8E0C-A84939240B9E Q24618086-DEB5050C-3A45-4BEF-8714-B532031301DA Q24646379-D3A4EC0D-5B11-4046-8405-921BDB3B3FCB Q24653343-754B2869-A5DF-4237-B0CF-36FA5E9D6A73 Q27006062-55A4223B-D87F-49DA-9720-B182339831AA Q27314782-6C905AEF-A65A-47BB-BDBC-DDA53494CB55 Q28256567-543857D7-DCC0-4ECE-BF23-40D600DD2EB3 Q33561185-AF523EF4-360B-44DB-81B7-4FB99F52EB4C Q33591789-DD2453DF-2CEF-4EE1-8496-276D6E2DA365 Q33856851-2B6940AC-DA60-434F-B471-5F8AFBF7923C Q34034292-C56FED44-2521-479B-A7C7-83F04D436613 Q34083101-2E1E81FA-4ED9-4146-8448-18E6042B5A33 Q34292361-FE0E96C7-21A0-437E-AB7B-063EA6C40DDE Q34302472-E18790B1-1161-4550-B420-AEA6A3CAA78C Q34314938-786F7C59-D225-4039-9C30-67084D40BE70 Q34390837-DD6A7464-0E79-4BC6-B723-3E509A85DAFB Q34617849-2AF6B8B4-0D35-48FE-BAFF-465FD68618E6 Q34679166-FD458493-911F-4B54-94AC-D24900856339 Q35145270-FCF8953C-DBD8-4E50-9197-6C960190F4EA Q35193836-480DE790-E922-4481-A043-1860AFE7A5EC Q35590607-210D0A47-2200-4B61-956C-FCFE9CEA3661 Q35739680-C19483BD-C443-4870-9D75-DB04C494B95F Q35811165-37C9B1BA-4AA6-4516-B26F-1F0DF8AFC870 Q35959252-064CE3F9-74CB-4EC5-8678-570E1D91B51F Q35974341-C8A34E00-2BF9-4CE7-A2CB-6ADFD8F7C2AB Q36194582-74B16363-6542-4482-AD21-9822A70807A1 Q36467468-59082359-DBF4-4F50-A6A5-D3A0E53BB7D2 Q36558579-74839D99-ACCA-474B-8771-0215B4ADDC00 Q36559885-954801F7-FF2A-4DF7-BFBB-87D82CA494FD Q36719078-A757F828-BC36-4210-92FD-A7041B558A55 Q36736636-CE1E98D3-0E89-4DDB-977D-7224190C58AC Q36787879-37FDA0C7-BF34-45F6-91B9-CED89B49CDB1 Q36799606-515DCDB5-9658-4AEA-B2F9-C2C5E20B659A Q36918646-5B0D9419-EC7E-4F39-8F25-AB2AB85F1E54 Q36949764-FA3C16B6-2E9B-4047-B3CE-D944476433DB Q36971217-3FDAE670-FEF0-4F8E-B61A-E2610CF985A3 Q36979534-A4A6BB94-55AF-4AA2-B3A6-E95D8357EF8C Q37020999-F841D4CB-47DB-4D24-AC26-1CDEDB3F4A4A Q37059428-DA5500F5-9384-4B01-AA35-2AFEBC6654EA Q37142412-0797A366-2BD3-4C96-8EEE-3E2272F7376B

P2860

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

http://www.wikidata.org/entity/Q53241753

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@en

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@nl

type

label

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@en

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@nl

prefLabel

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@en

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@nl

P1433

Q53241753-95024A87-2F87-4A53-81F6-2461D9240535

P1476

Q53241753-EE23599D-2794-44C0-B879-7858F1DBA587

P2093

Q53241753-551179CB-C4F6-413C-BBC3-EC61DB8DC169

Q53241753-609D92CD-AB86-4352-8B15-3797474FD450

Q53241753-89731784-2273-4B09-A00D-9519D2589D1A

Q53241753-945FD906-844E-42B8-A792-241410DEB271

Q53241753-B900422D-969D-4F79-B808-44C764825A4E

Q53241753-C2142B35-33A7-45F5-8D93-73720D300955

Q53241753-D475D36A-4304-4FC6-84BF-92C235F98ABE

Q53241753-DFEB3ED9-2C18-4C11-89D1-E500A2244574

P304

Q53241753-3170FF7C-8687-4597-8231-F85649F462DF

P31

Q53241753-3161567C-3B97-4F37-AE36-F5B3E6068DAD

P356

Q53241753-0CCA7774-BC74-4838-9404-6D7D5AE45AAD

P407

Q53241753-D6D862C3-036E-432A-8E46-39E83A6DC995

P433

Q53241753-312E2BDF-4C87-4D64-847D-A2239F283EFF

P478

Q53241753-16E33C2E-F6B4-4DA6-9112-BA4CDF20F169

P50

Q53241753-A3830D1A-A164-4F41-AFA9-A04D0193D4AB

P577

Q53241753-2681974C-097C-4B03-84CA-3576338FF6B1

P5875

Q53241753-65E08308-F7BD-4C71-B0B2-30D549339768

P698

Q53241753-11DCEB29-492B-41D4-BABF-1685F640D550

P921

Q53241753-C5AE017B-06DF-418E-9B30-B6B87E239B11

P356

BLOOD-2006-09-047068

P1433

P1476

Prognostic impact of immunohis ...... eated with immunochemotherapy.

@en

P2093

Gunilla Enblad

http://www.w3.org/2001/XMLSchema#string

Heidi Nyman

http://www.w3.org/2001/XMLSchema#string

Magdalena Adde

http://www.w3.org/2001/XMLSchema#string

Marja-Liisa Karjalainen-Lindsberg

http://www.w3.org/2001/XMLSchema#string

Mattias Berglund

http://www.w3.org/2001/XMLSchema#string

Minna Taskinen

http://www.w3.org/2001/XMLSchema#string

Rose-Marie Amini

http://www.w3.org/2001/XMLSchema#string

Sirpa Leppä

http://www.w3.org/2001/XMLSchema#string

P304

4930-4935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-09-047068

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6506497

http://www.w3.org/2001/XMLSchema#string

P698

17299093

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry